IL183227A0 - Use of lipid conjugates in the treatment of disease - Google Patents

Use of lipid conjugates in the treatment of disease

Info

Publication number
IL183227A0
IL183227A0 IL183227A IL18322707A IL183227A0 IL 183227 A0 IL183227 A0 IL 183227A0 IL 183227 A IL183227 A IL 183227A IL 18322707 A IL18322707 A IL 18322707A IL 183227 A0 IL183227 A0 IL 183227A0
Authority
IL
Israel
Prior art keywords
disease
treatment
lipid conjugates
conjugates
lipid
Prior art date
Application number
IL183227A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/989,607 external-priority patent/US7772196B2/en
Priority claimed from US10/989,606 external-priority patent/US7811999B2/en
Priority claimed from PCT/US2005/006591 external-priority patent/WO2005084307A2/en
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL183227A priority Critical patent/IL183227A0/en
Publication of IL183227A0 publication Critical patent/IL183227A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL183227A 2004-11-17 2007-05-15 Use of lipid conjugates in the treatment of disease IL183227A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL183227A IL183227A0 (en) 2004-11-17 2007-05-15 Use of lipid conjugates in the treatment of disease

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/989,607 US7772196B2 (en) 2000-01-10 2004-11-17 Use of lipid conjugates in the treatment of diseases
US10/989,606 US7811999B2 (en) 2000-01-10 2004-11-17 Use of lipid conjugates in the treatment of diseases
PCT/US2005/006591 WO2005084307A2 (en) 2004-03-02 2005-03-02 Use of lipid conjugates in the treatment of disease
PCT/IL2005/001225 WO2006054304A2 (en) 2004-11-17 2005-11-17 Use of lipid conjugates in the treatment of disease
IL183227A IL183227A0 (en) 2004-11-17 2007-05-15 Use of lipid conjugates in the treatment of disease

Publications (1)

Publication Number Publication Date
IL183227A0 true IL183227A0 (en) 2007-08-19

Family

ID=39619055

Family Applications (3)

Application Number Title Priority Date Filing Date
IL183227A IL183227A0 (en) 2004-11-17 2007-05-15 Use of lipid conjugates in the treatment of disease
IL212214A IL212214A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease
IL212215A IL212215A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL212214A IL212214A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease
IL212215A IL212215A0 (en) 2004-11-17 2011-04-07 Use of lipid conjugates in the treatment of disease

Country Status (10)

Country Link
EP (1) EP1819345A4 (de)
JP (2) JP2008520650A (de)
CN (1) CN101175499B (de)
AU (1) AU2005305456B2 (de)
BR (1) BRPI0516810A (de)
CA (1) CA2587883A1 (de)
EA (1) EA012138B1 (de)
IL (3) IL183227A0 (de)
MX (1) MX2007005975A (de)
WO (1) WO2006054304A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090325876A1 (en) * 2004-09-29 2009-12-31 Saul Yedgar Use of lipid conjugates in the treatment of diseases associated with vasculature
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
JP2012526819A (ja) * 2009-05-11 2012-11-01 イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド 脂質−ポリマー複合体、その調製、及びその使用
CA3153463A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
EP3020417A4 (de) * 2013-07-10 2017-01-18 Seikagaku Corporation Pharmazeutische zusammensetzung zur respiratorischen verabreichung
EP4292651A3 (de) * 2016-06-27 2024-03-13 Ohio State Innovation Foundation Liponukleotidbasierte therapie für ards
CN110198728A (zh) 2016-11-17 2019-09-03 莱诺翁股份有限公司 用谷胱甘肽组合物治疗呼吸道疾病和感染
DK3710036T3 (da) 2017-11-17 2025-01-13 Renovion Inc Stable ascorbic acid compositions and methods of using the same
JP2025502856A (ja) 2022-01-04 2025-01-28 レノビオン インコーポレイテッド グルタチオン塩を含む水溶液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84252A (en) * 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
JPH0232013A (ja) * 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk 点鼻剤
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
ES2044781B1 (es) * 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
KR100381449B1 (ko) * 1994-10-14 2003-07-18 더 리포좀 컴퍼니, 인코퍼레이티드 에테르지질리포좀과이들의제약학적용도
US6180596B1 (en) * 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
JPH11147901A (ja) * 1997-11-19 1999-06-02 Maruho Co Ltd カリクレイン−キニン系阻害剤
US6162787A (en) * 1999-04-02 2000-12-19 Immudyne, Inc. Methods for treating arthritis using collagen type II, glucosamine chondroitin sulfate, and compositions
US7101859B2 (en) * 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
CA2397016C (en) * 2000-01-10 2011-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US7141552B2 (en) * 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases

Also Published As

Publication number Publication date
JP2012001559A (ja) 2012-01-05
EA200701077A1 (ru) 2008-04-28
EP1819345A2 (de) 2007-08-22
WO2006054304A2 (en) 2006-05-26
CA2587883A1 (en) 2006-05-26
IL212214A0 (en) 2011-06-30
JP2008520650A (ja) 2008-06-19
MX2007005975A (es) 2007-10-08
IL212215A0 (en) 2011-06-30
AU2005305456B2 (en) 2011-05-19
WO2006054304A3 (en) 2007-01-25
EP1819345A4 (de) 2012-04-18
CN101175499B (zh) 2010-12-22
EA012138B1 (ru) 2009-08-28
AU2005305456A1 (en) 2006-05-26
BRPI0516810A (pt) 2008-09-23
CN101175499A (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
IL184884A0 (en) Extending time or disease progression or survival in cancer patients
GB0410725D0 (en) Pyrrolobenzodiazepine therapeutic agents
IL180078A (en) Derivatives of 9-cis retinal for use in treating deficiency of 11-cis retinal
IL150628A0 (en) Use of lipid conjugates in the treatment of disease
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
EP2094281A4 (de) Verwendung von lipidkonjugaten bei der behandlung von krankheiten oder erkrankungen des auges
EP1957462A4 (de) Neue 2-amino-heterozyklen nützlich zur behandlung von abeta-verwandten krankheiten
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
PL1885380T3 (pl) Metaarsenian sodu do stosowania w leczeniu przerzutowych chorób nowotworowych
EP1874800A4 (de) Diagnostische und therapeutische mittel
IL181300A0 (en) Photosensitizer formulations and uses thereof
EP1757282A4 (de) Verwendung von kaurane-verbindungen bei der herstellung von medikamenten
SI1807156T1 (sl) Nove farmacevtske oblike za uporabo pri zdravljenju nespečnosti
IL185575A0 (en) Benzoxazocines and their therapeutic use
IL229982A0 (en) Use of fatty conjugates to treat diseases
IL229980A0 (en) Use of fatty conjugates to treat diseases
IL229981A0 (en) Use of fatty conjugates to treat diseases
GB0501655D0 (en) Therapeutic use
HK1102108A (en) Use of lipid conjugates in the treatment of diseases
EP1951914A4 (de) Diagnose- und therapieverfahren und -mittel
GB0402598D0 (en) Improvements in or relating to patient support
EP1956001A4 (de) Pharmazeutikum zur verwendung bei der behandlung von ureterolithiasis
HK1111892A (en) Use of pyrazolyl-pyrimidine derivatives in the treatment of pain